𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinib

✍ Scribed by R.M. Van Hest; J.B. Schnog; M.B. Van't Veer; J.J. Cornelissen

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
306 KB
Volume
83
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dasatinib 140 mg once daily versus 70 mg
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study
✍ Michael B. Lilly; Oliver G. Ottmann; Neil P. Shah; Richard A. Larson; Josy J. Re 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 1 views

## Abstract Dasatinib 70 mg twice daily is indicated for Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) intolerant or resistant to imatinib. In patients with chronic‐phase chronic myelogenous leukemia, once‐daily dosing has similar efficacy with improved safety, compared wi

A novel gene, FGA7, is fused to RUNX1/AM
A novel gene, FGA7, is fused to RUNX1/AML1 in a t(4;21)(q28;q22) in a patient with T-cell acute lymphoblastic leukemia
✍ Fady M. Mikhail; Lionel Coignet; Nadia Hatem; Zeinab I. Mourad; Hala M. Farawela 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 517 KB

## Abstract __AML1__ is among the most frequent targets of chromosomal rearrangements in human leukemias. We report here the molecular analysis of a t(4;21)(q28;q22) that has disrupted __AML1__ in a patient with de novo T‐cell acute lymphoblastic leukemia. By using 3′‐RACE analysis, we show that th